Price movement over the last 24 hours
AbCellera Biologics Inc vs Target Corporation — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while Target Corporation trades at $132.5 (market cap $57.93B). The key difference: Target Corporation is far larger — about 24.7× AbCellera Biologics Inc's market cap, and Target Corporation pays a 3.64% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TGT | |
|---|---|---|
Market Cap | $2.35B | $57.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $141.19 |
52-Week Low | $2.78 | $83.68 |
Enterprise Value | $1.99B | $73.23B |
Dividend Yield | — | 3.64% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →